Departamento de Fisiología y Farmacología, Facultad de Medicina, Universidad de Cantabria, 39011 Santander, Spain.
Instituto Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Int J Mol Sci. 2024 Oct 24;25(21):11427. doi: 10.3390/ijms252111427.
Neuropathic pain is a prevalent and debilitating chronic syndrome that is often resistant to treatment. It frequently arises as a consequence of damage to first-order nociceptive neurons in the lumbar dorsal root ganglia (DRG), with chromatolysis being the primary neuropathological response following sciatic nerve injury (SNI). Nevertheless, the function of miRNAs in modulating this chromatolytic response in the context of neuropathic pain remains unexplored. Our previous research demonstrated that the intracisternal administration of a miR-30c mimic accelerates the development of neuropathic pain, whereas the inhibition of miR-30c prevents pain onset and reverses established allodynia. In the present study, we sought to elucidate the role of miR-30c-5p in the pathogenesis of neuropathic pain, with a particular focus on its impact on DRG neurons following SNI. The organisation and ultrastructural changes in DRG neurons, particularly in the protein synthesis machinery, nucleolus, and Cajal bodies (CBs), were analysed. The results demonstrated that the administration of a miR-30c-5p mimic exacerbates chromatolytic damage and nucleolar stress and induces CB depletion in DRG neurons following SNI, whereas the administration of a miR-30c-5p inhibitor alleviates these effects. We proposed that three essential cellular responses-nucleolar stress, CB depletion, and chromatolysis-are the pathological mechanisms in stressed DRG neurons underlying neuropathic pain. Moreover, miR-30c-5p inhibition has a neuroprotective effect by reducing the stress response in DRG neurons, which supports its potential as a therapeutic target for neuropathic pain management. This study emphasises the importance of miR-30c-5p in neuropathic pain pathogenesis and supports further exploration of miRNA-based treatments.
神经病理性疼痛是一种普遍且使人虚弱的慢性综合征,通常对治疗有抗性。它常由腰背部脊神经节(DRG)中第一级伤害感受神经元损伤引起,坐骨神经损伤(SNI)后发生的溶酶体反应是主要的神经病理学反应。然而,miRNA 在调节神经病理性疼痛中这种溶酶体反应的功能仍未被探索。我们之前的研究表明,脑室内给予 miR-30c 模拟物会加速神经病理性疼痛的发展,而抑制 miR-30c 可以预防疼痛发作并逆转已建立的痛觉过敏。在本研究中,我们试图阐明 miR-30c-5p 在神经病理性疼痛发病机制中的作用,特别是其对 SNI 后 DRG 神经元的影响。分析了 DRG 神经元的结构和超微结构变化,特别是在蛋白质合成机制、核仁、Cajal 体(CB)。结果表明,给予 miR-30c-5p 模拟物会加剧 SNI 后 DRG 神经元的溶酶体损伤和核仁应激,并导致 CB 耗竭,而给予 miR-30c-5p 抑制剂则可以减轻这些影响。我们提出,三个重要的细胞反应——核仁应激、CB 耗竭和溶酶体反应,是神经病理性疼痛中应激性 DRG 神经元的病理机制。此外,miR-30c-5p 抑制通过减少 DRG 神经元的应激反应具有神经保护作用,这支持了其作为神经病理性疼痛管理治疗靶点的潜力。本研究强调了 miR-30c-5p 在神经病理性疼痛发病机制中的重要性,并支持进一步探索基于 miRNA 的治疗方法。